08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

Optomagic, Korean Research Institute of Bioscience and Biotechnology deal

Optomagic’s Chemizon Inc. drug discovery services division and the institute will form a new company to commercialize the institute’s IP, initially focusing on cancer, CNS and infectious diseases. Chemizon will be the lead investor in...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Array BioPharma, Optomagic Co. Ltd. deal

Optomagic's Chemizon Inc. unit will provide medicinal chemistry services to support ARRY's drug discovery programs. Further terms were not disclosed. Array BioPharma Inc. (ARRY), Boulder, Colo.   Optomagic Co. Ltd. (KOSDAQ:010170), Ansan, South Korea  ...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Discovery Lab board of directors update

(DSCO completes merger with ANSN, see B4) Discovery Laboratories Inc. (DSCO), New York, N.Y.   Business: Pulmonary, Metabolic   Appointed: James Kuo, president and CEO; Evan Myrianthopoulos, COO; Vaughan Shalson, former president and CEO of...
08:00 , Dec 8, 1997 |  BC Week In Review  |  Company News

Ansan, Discovery Lab deal

ANSN and Discovery Laboratories, a developer of drugs to treat critical respiratory conditions, completed their previously announced merger (see BioCentury, July 21). Discovery shareholders own 92 percent of the combined company on a fully diluted...
07:00 , Jul 21, 1997 |  BC Week In Review  |  Company News

Ansan, Discovery Lab, Titan deal

ANSN will merge with privately held Discovery Laboratories, a developer of drugs to treat critical respiratory conditions. ANSN plans to issue common shares in the transaction. In addition, Discovery Laboratories will purchase ANSN convertible preferred...
07:00 , Apr 7, 1997 |  BC Week In Review  |  Company News

Ansan, Titan deal

The companies amended their financing agreement, under which TTNP was to invest up to $8 million in ANSN over the next two years. As amended, TTNP advanced $1 million to ANSN, which is convertible at...
08:00 , Feb 24, 1997 |  BC Week In Review  |  Company News

Ansan management update

Ansan Pharmaceuticals Inc. (ANSNU), South San Francisco, Calif.   Business: Cancer, Hematology   Hired: Vaughan Shalson, as president and CEO; formerly president and CEO of Molecular Devices Corp.  ...
08:00 , Dec 23, 1996 |  BC Week In Review  |  Company News

Ansan, Titan deal

The companies signed a letter of intent providing for TTNP to invest up to $8 million in ANSN over the next two years. TTNP is ANSN's largest shareholder, owning 43 percent. The initial investment will...
08:00 , Nov 18, 1996 |  BC Week In Review  |  Clinical News

Pivanex analog of butyric acid data

ANSNU announced interim analysis of a Phase Ib trial in which half of the planned dose levels have been given. One of 3 patients with lung cancer has had a 50 percent reduction in tumor...
08:00 , Nov 11, 1996 |  BC Week In Review  |  Clinical News

Ansan regulatory update

ANSNU received U.S. Patent No. 5,569,675 covering Novaheme Injection (AN10) to treat red blood cell disorders such as sickle cell disease and beta thalassemia. Novaheme is an analog of butyrate, a salt of a saturated...